LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant…

Overview of attention for article published in Clinical Lung Cancer, March 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#3 of 1,223)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 11,879 followers.

RT @Boehringer: #HCP LUME-Meso phase III trial design and rationale for patients with mesothelioma now published #ClinicalLungCancer https:…

RT @Boehringer: #HCP LUME-Meso phase III trial design and rationale for patients with mesothelioma now published #ClinicalLungCancer https:…

RT @Boehringer: #HCP LUME-Meso phase III trial design and rationale for patients with mesothelioma now published #ClinicalLungCancer https:…

RT @Boehringer: #HCP LUME-Meso phase III trial design and rationale for patients with mesothelioma now published #ClinicalLungCancer https:…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.